# Interferon-α for Immune Modulation in Chronic Hepatitis B Toward Functional Cure

## TL;DR

This paper reviews how interferon-alpha can help treat chronic hepatitis B by boosting the immune system and suggests new strategies to improve treatment outcomes.

## Contribution

The paper highlights recent advances in cytokine engineering and combination therapies to optimize interferon-alpha-based treatments for chronic hepatitis B.

## Key findings

- Interferon-alpha can reprogram immune responses to promote viral clearance in chronic hepatitis B.
- Combination strategies with interferon-alpha improve treatment outcomes despite modest response rates.
- Cytokine engineering and subtype research offer new opportunities for functional cure of chronic hepatitis B.

## Abstract

Chronic hepatitis B (CHB) remains a major global health challenge, largely due to the persistence of covalently closed circular DNA (cccDNA) and impaired host immunity. Interferon-α (IFN-α), a key antiviral cytokine, not only directly restricts HBV replication but also orchestrates innate and adaptive immune responses. This review summarizes current advances in IFN-α-mediated immune regulation, highlighting its effects across diverse immune cell populations. Evidence indicates that IFN-α can reprogram immune responses to promote viral clearance, although clinical efficacy is limited by modest response rates and adverse effects. Recent progress in cytokine engineering, subtype research, and rational combination strategies—including nucleo(s/t)ide analogs, RNA interference therapeutics, antisense oligonucleotides, therapeutic vaccines, and beyond—has expanded opportunities to improve treatment outcomes. While challenges remain, these advances lay the foundation for optimizing IFN-α–based interventions and highlight IFN-α as a key driver for innovative therapies aimed at achieving a functional cure of chronic hepatitis B.